INTRODUCTION
This supplementary appendix contains additional materials that were not presented in the manuscript and provides detailed information about various topics mentioned in the article. In Section 2 we present the complete results of the simulation study discussed in Section 5 in the manuscript. In Section 3 we present materials related to the likelihood ratio test (LRT) while Section 4 is devoted to the multiple contrast tests (MCT). Design matrices related to the BVS model are presented in Section 5 and an additional case study, analysis of dose-response microarray experiment, is presented in Section 6.
SIMULATION RESULTS
The simulation settings correspond to the setting used by Marcus (1976) , except for the ordering of the models and more λ values. The values for all profiles of K = 5 (Table 11) were derived in the same way as for K = 4. The setting matrices (Table 12 and Table 13) were multiplied by λ to cover diverse relative differences among the dose levels. Using λ = 0 shows behaviour under the null model, for the alternative models we set λ = 1, 1.5, 2, 2.5, 3. Afterwards, for each setting, 1000 data were generated. Each dataset contains four dose levels (control included) with varying number of samples (n = 3, 4, 5) per dose. The noise followed a standard normal distribution. All the methods were applied under the assumption of the monotone upward trend for investigating the power and under the null model for investigating the Type I error. One-sided tests were run for the MCTs and the LRT. For K = 4 and n = 4, simulation was repeated with different choices of variance of Gaussian distribution ( Figure 5 ). Table 1 and Tables 2  and 3 as well. The BVS posterior probabilities are higher in absolute values comparing the p-values, hence to achieve similar results (in terms of the power, the Type I error or the number of significant genes identified) the higher threshold than 0.05 has to be used for the BVS. Note that with an increasing n, the overall power increases and the difference among the methods diminishes in a similar way as with the increasing λ. The behavior of Type I error is shown in Figure 5 . Visualization of the results is shown in Figure 6 for all n = 3, 4, 5. The corresponding results for K = 5 are provided in Tables 4, 5, 6, 7, 8 and 9 . 1.00 1.00 1.00 1.00 1.00 1.00 0.87 g 3 1.00 1.00 1.00 1.00 1.00 1.00 0.67 g 4 1.00 1.00 1.00 1.00 1.00 1.00 0.90 g 5 1.00 1.00 1.00 1.00 1.00 1.00 0.85 g 6 1.00 0.99 1.00 0.99 1.00 1.00 0.67 g 7
1.00 1.00 1.00 1.00 1.00 1.00 0.15 Table 3 : Results for n = 5. Columns LRT and MCTs show estimation of the power of the particular tests. Columns BVS shows proportion of the (mean of) posterior probabilities of the null model given the data that are smaller then α = 0.05, 0.10, 0.15. Last column represent the estimated probability of the correct model having the highest mean of the posterior probability among all the possible models. 1.00 1.00 1.00 0.99 1.00 1.00 0.90 g 3 1.00 1.00 1.00 0.99 1.00 1.00 0.57 g 4 1.00 0.99 1.00 0.99 1.00 1.00 0.90 g 5 1.00 1.00 1.00 0.99 1.00 1.00 0.79 g 6 1.00 1.00 1.00 1.00 1.00 1.00 0.59 g 7
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1.00 1.00 1.00 1.00 1.00 1.00 0.23 Table 4 : Results for K = 5, n = 3, part 1. Columns LRT and MCTs show estimation of the power of the particular tests. Columns BVS shows proportion of the (mean of) posterior probabilities of the null model given the data that are smaller then α = 0.05, 0.10, 0.15. Last column represent the estimated probability of the correct model having the highest mean of the posterior probability among all the possible models. Table 5 : Results for K = 5, n = 3, part 2. Columns LRT and MCTs show estimation of the power of the particular tests. Columns BVS shows proportion of the (mean of) posterior probabilities of the null model given the data that are smaller then α = 0.05, 0.10, 0.15. Last column represent the estimated probability of the correct model having the highest mean of the posterior probability among all the possible models. 1.00 1.00 0.99 0.99 1.00 1.00 0.77 g 10 1.00 0.99 1.00 0.99 1.00 1.00 0.61 g 11 1.00 1.00 1.00 1.00 1.00 1.00 0.10 g 12 1.00 0.97 0.99 0.99 1.00 1.00 0.48 g 13 1.00 0.99 0.99 0.99 1.00 1.00 0.12 g 14 1.00 0.99 1.00 1.00 1.00 1.00 0.04 g 15 1.00 0.99 1.00 1.00 1.00 1.00 0.00 Table 6 : Results for K = 5, n = 4, part 1. Columns LRT and MCTs show estimation of the power of the particular tests. Columns BVS shows proportion of the (mean of) posterior probabilities of the null model given the data that are smaller then α = 0.05, 0.10, 0.15. Last column represent the estimated probability of the correct model having the highest mean of the posterior probability among all the possible models. Table 7 : Results for K = 5, n = 4, part 2.Columns LRT and MCTs show estimation of the power of the particular tests. Columns BVS shows proportion of the (mean of) posterior probabilities of the null model given the data that are smaller then α = 0.05, 0.10, 0.15. Last column represent the estimated probability of the correct model having the highest mean of the posterior probability among all the possible models. 1.00 0.99 1.00 0.99 1.00 1.00 0.00 3 g 1 1.00 1.00 1.00 1.00 1.00 1.00 0.89 g 2 1.00 1.00 1.00 1.00 1.00 1.00 0.85 g 3 1.00 1.00 1.00 1.00 1.00 1.00 0.59 g 4 1.00 0.99 1.00 1.00 1.00 1.00 0.86 g 5 1.00 1.00 1.00 1.00 1.00 1.00 0.71 g 6 1.00 1.00 1.00 1.00 1.00 1.00 0.57 g 7
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1.00 1.00 1.00 1.00 1.00 1.00 0.00 Table 8 : Results for K = 5, n = 5, part 1. Columns LRT and MCTs show estimation of the power of the particular tests. Columns BVS shows proportion of the (mean of) posterior probabilities of the null model given the data that are smaller then α = 0.05, 0.10, 0.15. Last column represent the estimated probability of the correct model having the highest mean of the posterior probability among all the possible models. Table 9 : Results for K = 5, n = 5, part 2. Columns LRT and MCTs show estimation of the power of the particular tests. Columns BVS shows proportion of the (mean of) posterior probabilities of the null model given the data that are smaller then α = 0.05, 0.10, 0.15. Last column represent the estimated probability of the correct model having the highest mean of the posterior probability among all the possible models. 1.00 1.00 1.00 1.00 1.00 1.00 0.81 g 10 1.00 0.99 1.00 1.00 1.00 1.00 0.68 g 11
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LIKELIHOOD RATIO TEST
The likelihood ratio test is discussed in Section 3.1 in the manuscript. The null distribution of T LRT is a mixture of Beta distributions with mixture probabilities P ( , K, w), = 1, . . . , K, that are also known as the level probabilities. They represent the probability (under the null hypothesis) that the number of unique isotonic means equals to in an experiment with K possible levels. According to Barlow et al. (1972) , the p-value can be calculated by
with N being the total number of observations, the number of final levels and B1 K ) equals the variance of the response at each dose. For example, for case of K = 4 and equal weights w 0 , the probability for one level only equals P ( = 1, 4, w 0 ) = 0.25, P ( = 2, 4, w 0 ) = 0.46, P ( = 3, 4, w 0 ) = 0.25 and P ( = 4, 4, w 0 ) = 0.04 (Robertson et al. 1988) . Note that level probabilities themselves are related to the isotonic regression results and not to the testing of the null hypothesis. They show the probability of obtaining certain number of the isotonic means under the null hypothesis. Hence, they do not depend on the variability of the data unless the variability differs across the doses.
MULTIPLE CONTRAST TESTS
In this section we discuss in more details the contrast matrices for the MCT introduced in Section 3.1 in the manuscript. The MCT for the set of the single contacts tests (T
can be defined using a contrast matrix given by
Each row of the contrast matrix C M C corresponds to one contrast vector c of the SCT. There exist lot of useful choices of the contrast matrices (Hothorn 2006, e.g.) . For the further comparison, we use two of them: Williams' and Marcus' MCTs (Bretz 1999) based on the tests designed by Williams (1971) and Marcus (1976) . Designs of the tests determine the choice of c v , v = 1, . . . , V . Williams' MCT is based on the comparison between first (usually control) dose and the weighted average over the last b (b = 1, ..., K − 1) doses. It originates from a comparison of the last dose meanμ K−1 computed using the isotonic regression with an estimate of the mean of the first doseμ 0 under the different possible profiles. Hence, due to properties of the PAVA algorithm it holds that
The matrix C W il we call a Williams-type MCT matrix and we use it to construct our set of the MCTs through Equation (3).
Marcus' MCT is a modification of Williams' idea with replacing the estimate of the mean of the first doseμ 0 with the isotonic estimateμ 0 . Unfortunately, there is no general close form solution for C as in case of Williams, since its structure depends on the number of the doses. It can be easily constructed using each element of the following relationship as one contrast:
The inference of Williams' and Marcus' MCTs can be based on the multivariate t-distribution.
For the details about the distribution and about both procedures, we recommend to see Lin et al. (2012) .
BAYESIAN VARIABLE SELECTION
Design Matrices
As mentioned in the manuscript in Section 1 and Section 3, the BVS models fits all possible one-way ordered restricted ANOVA models for a given value of K. Each one of the models is defined using a model specific design matrix and a parameter vector. For example, for an experiment with K = 4 dose levels, the design matrices for all the models presented in Table 1 are given, respectively, by 
The mean gene expression for each model g r is given by
where β r is the parameter vector for each model given by
model g 3 , (µ 0 , δ 3 ) , model g 4 , (µ 0 , δ 1 , δ 3 ) , model g 5 , (µ 0 , δ 2 , δ 3 ) , model g 6 , (µ 0 , δ 1 , δ 2 , δ 3 ) model g 7 .
MULTIPLICITY ADJUSTMENT
The HESCA Study
The HESCA dataset (Bijnens et al. 2012 ) describes results of a dose-response microarray experiment. Human epidermal squamous carcinoma cell line A431 (HESCA431) was grown and cells were stimulated with the growth factor EGF at four concentrations (including placebo) for 24 hours. The gene expression level was measured using GeneChip (Affymetrix). The dataset contains 12 arrays, three arrays for each of four dose levels with 16,998 genes. For details about methodology and preprocessing including normalization, see Bijnens et al. (2012) . The aim of the analysis of the HESCA dataset is to detect genes with monotone expression profiles.
The Direct Posterior Probability Approach for Multiplicity
Adjustment.
Due to a high dimensionality of microarray data, the dose-response microarray analysis of the HESCA study requires multiplicity adjustment both within and between genes. Typically, the family wise error rate (FWER) that represents the overall Type I error, i.e., the probability of at least one false rejection of the null hypothesis, and the false discovery rate (FDR), i.e., the expected proportion of the false rejections among all the rejections, are used for the multiplicity adjustment. Following Lin et al. (2012) we apply the FWER method for the multiplicity adjustment within the genes and the FDR for the multiplicity adjustment between the genes. In the following section, we discuss the use of the posterior probability of the null model for the FDR adjustment within the BVS framework.
Assume that there are m = 1, . . . , M genes to analyze simultaneously and the aim is to identify genes that exhibit a monotone relationship with increasing doses of a therapeutic compound. The problem is equivalent to investigating if expression levels of each gene show substantive evidence against the null model g 0 . The posterior probability of the null model P m (g 0 |data) holds dual properties as the likelihood of the null model and simultaneously the probability of the false rejection of the null hypothesis when the gene is considered to have the monotone profile (Newton et al. 2007 ). For a pre-specified threshold α, P m (g 0 |data) represents probability of the false positive for the gene m. Let I m be an indicator variable of P m (g 0 |data) ≤ α (i.e., indicator of including gene among genes with "significant" doseresponse relationship). The expected number of the false discoveries (cFD) is cFD(α) := E(cFD) = 
where N (α) is the number of genes declared significant for a given threshold α. Then, the cFDR(α) represents a mean error made by considering any gene as significant using the threshold α. Hence, we select a value of α in a way to keep the cFDR(α) under the prespecified threshold τ . Figure 9 shows the relationship between the false discovery rate, the number of significant genes and the threshold for the HESCA case study. As expected, the higher the threshold, the higher the cFDR and the number of significant genes. The implication of this relationship is that in order to control for a certain level of the cFDR, the corresponding threshold can be used as significance level for the posterior probability under the null model. Note that the concept of the significance level as used here is data dependent and consequently, the cFDR control is conditional on the data. Table 10 shows the number of genes with the significant dose-relationship under the upward and downward monotone profiles from the HESCA study. The number of genes with the significant dose-response relationship is higher for the frequentist methods than the BVS model at 5% false discovery rate. At a fixed level of FDR, the higher number of the significant genes for the frequentist methods may imply the better power with these methods than with the BVS model since the power is often associated with the number of the significant genes. However, the FDR controlled by the frequentist methods and the cFDR introduced for the BVS context are not entirely same quantities, since one arise from an adjustment of p-values and other one from an adjustment of the posterior probabilities of the null model. The comparison of the BVS model and the frequentists methods in terms of the Type I error and the power is investigated through a simulation study presented in the next section. 
